Market Vectors Gold Miners ETF (GDX) Message Board

Fanapt® (iloperidone)

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

why are they even bringing up that option if they felt TTNP had a winner?

People are selling because this is TTNP's only product and if it fail, so does TTNP, apparantely..

read up on penny gold, BONZ

go to "JuniorGoldMinersReport" and see for yourself...

that's what it says about penny gold, BONZ

go to "JuniorGoldMinersReport" and see for yourself...

unreal people do not know about this...

Presently the share price is basing at $0.01 with relative strength indicators, including the RSI and the MACD trending up - supportive of a higher share price in the future.

We believe the current market capitalization does not represent the fair value of Bonanza's 600-acre contiguous land package bordering the historic Congress Mine. We valued Bonanza Goldfields using a comparative valuation method based on a multiple representing peers’ median market claim value they report for their projects.

We selected five junior mining companies that in our opinion are similar to Bonanza Goldfields in terms of
project development stage and minerals explored (gold and silver). This analysis resulted in an estimate of the Tarantula claims being valued
at $12 million when evaluated relative to comparable claims, then minus the companies present liabilities of $1.6 million, values this company modestly at $0.045/share - 400% above where the stock currently trades at $0.0086/share. Once the extent of the gold reserves are modeled, our estimation is the stock could easily trade in the $0.12 - $0.15/share range - at least 1,200% above the current share price.

This price appreciation could occur within a 9-month window, based on the new gold findings highlighted above

Bonanza
Goldfield's 4/4/13 Press Release announcing significant lode
concentrations in large exposed quartz veins being identified - is
impressive, with verified assays ranging from .007 to 2.73 oz/ton.
Meeting with management and a site visit confirms their focus is shifting
to principally lode processing as opposed to previous placer
exploration/production that is yielding more modest results. This junior
miner is located about 1½ hours NW of Phoenix – on patent claims
adjacent to the Congress Mine, a mine that historically produced
396,300 ounces of gold primarily from 1887 – 1912 and later reopened
and operated through 1959. As the company gains more visibility in the
public market and attracts more investors, it should trade more in line
with its peers at $1.75/share. If Bonanza Goldfields works out, I see lots
of upside and if it doesn't work out, I see only minimal downside as it
presently trades at a modest market cap of $1.61 million with a 230
million share float. Management is unproven in a junior and a bit
arrogant (or confident?) as to their abilities to make this junior a big
success - although I judge them as capable of it.

JuniorGoldMinersReport website